Skip to main content
Log in

AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level

  • Reproductive Physiology and Disease
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript



We explored whether AMH, as a surrogate for oocyte supply, varies by FMR1 genotype in women diagnosed with diminished ovarian reserve (DOR), a subset of the Primary Ovarian Insufficiency phenotype. Research is inconsistent on the relationship between AMH and FMR1 repeat length, controlling for age.


Seventy-nine cycling women diagnosed with DOR, and without a family history of fragile X syndrome, provided blood for FMR1 and AMH testing. DOR was defined as elevated FSH and/or low AMH and/or low antral follicle count, with regular menses. FMR1 CGG repeats were stratified by the larger allele <35 repeats (n = 70) v. ≥35 repeats (n = 9). Quadratic and linear models were fit to predict log (AMH) controlling for age. The AMH sample used as the outcome variable was drawn at a later date than the diagnostic AMH.


Serum AMH concentration median was 0.30 ng/mL; Ages ranged from 26–43 years. A quadratic model (including age2) did not show a relationship with FMR1 CGG level (p-value = 0.25). A linear model of log (AMH), corresponding to an exponential decline of AMH with increasing age, was significantly different, and had a steeper slope, for women with ≥ 35 CGG repeats than women with < 35 repeats (p = 0.035).


Findings suggest a greater rate of follicular loss that starts at later ages in women with DOR and ≥ 35 CGG repeats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others


  1. Broer SL, Eijkemans MJC, Scheffer GJ, van Rooij IAJ, de Vet A, Themmen APN, et al. Anti-Müllerian Hormone Predicts Menopause: A Long-Term Follow-Up Study in Normoovulatory Women. J Clin Endocrin Metab. 2011;96(8):2532–9. doi:10.1210/jc.2010-2776.

    Article  CAS  Google Scholar 

  2. Choe SA, Kim KC, Lee JY, Kim CH, Hwang D, Jee BC. The relationship between the number of CGG repeats and serum level of anti-Mullerian hormone in women without FMR1 premutation. Eur J Obstet Gynecol Reprod Biol. 2013. doi:10.1016/j.ejogrb.2013.05.002.

    PubMed  Google Scholar 

  3. De Geyter C, M’Rabet N, De Geyter J, Zurcher S, Moffat R, Bosch N, et al. Similar prevalence of expanded CGG repeat lengths in the fragile X mental retardation I gene among infertile women and among women with proven fertility: a prospective study. Genetics in Med. 2013. doi:10.1038/gim.2013.146.

    Google Scholar 

  4. Friese C, Becker G, Nachtigall RD. Rethinking the biological clock: eleventh-hour moms, miracle moms and meanings of age-related infertility. Social Sci Med. 2006;63(6):1550–60.

    Article  Google Scholar 

  5. Gleicher N, Weghofer A, Barad DH. A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. Fertil Steril. 2009;91(5):1700–6. doi:10.1016/j.fertnstert.2008.01.098.

    Article  PubMed  CAS  Google Scholar 

  6. Gleicher N, Weghofer A, Oktay K, Barad DH. Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: A new infertility test? Acta Obstet Gynecol Scand. 2009;88(9):1024–30. doi:10.1080/00016340903171058.

    Article  PubMed  CAS  Google Scholar 

  7. Hadlow N, Longhurst K, McClements A, Natalwala J, Brown SJ, Matson PL. Variation in antimüllerian hormone concentration during the menstrual cycle may change the clinical classification of the ovarian response. Fertil Steril. 2013;99(6). doi:10.1016/j.bbr.2011.03.031

  8. Hansen KR, Hodnett GM, Knowlton N, Craig LB. Correlation of ovarian reserve tests with histologically determined primordial follicle number. Fertil Steril. 2011;95(1):170–5. doi:10.1016/j.fertnstert.2010.04.006.

    Article  PubMed  Google Scholar 

  9. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-Mullerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrin Metab. 2006;91(10):4057–63.

    Article  CAS  Google Scholar 

  10. Iino K, Tarakida A, Abe K, Taniguchi R, Higuchi T, Takahashi I, et al. Role of antimullerian hormone as a biomarker of the menopausal transition. Menopause. 2013;20(2):218–22. doi:10.1097/gme.0b013e3182611574.

    PubMed  Google Scholar 

  11. Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS. Antimullerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril.99(5):1305–10

  12. Karimov CB, Moragianni VA, Cronister A, Srouji S, Petrozza J, Racowsky C, et al. Increased frequency of occult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function. Hum Reprod. 2011;26(8):2077–83.

    Article  PubMed  CAS  Google Scholar 

  13. Kline JK, Kinney AM, Levin B, Brown SA, Hadd AG, Warburton D. Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age. Menopause. 2014. doi:10.1097/gme.0000000000000139

  14. Leader B, Hegde A, Baca Q, Stone K, Lannon B, Seifer DB, et al. High frequency of discordance between antimullerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers. Fertil Steril. 2012;98(4):1037–42.

    Article  PubMed  CAS  Google Scholar 

  15. Levi AJ, Raynault MF, Bergh PA, Drews MR, Miller BT, Scott Jr RT. Reproductive outcome in patients with diminished ovarian reserve. Fertil Steril. 2001;76(4):666–9.

    Article  PubMed  CAS  Google Scholar 

  16. Nelson SM, La Marca A. The journey from the old to the new AMH assay: how to avoid getting lost in the values. Repro Biomed Online. 2011;23(4):411–20.

    Article  CAS  Google Scholar 

  17. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A. Nomogram for the decline in serum antimüllerian hormone: a population study of 9,601 infertility patients. Fertil Steril. 2011;95(2):736–41. doi:10.1016/j.fertnstert.2010.08.022. e3.

    Article  PubMed  CAS  Google Scholar 

  18. Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G et al. The impact of oral contraceptives and metformin on anti-Mullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. Gynecol Endocrinol.27(8):587–92

  19. Pastore LM, Young SL, Baker VM, Karns LB, Williams CD, Silverman LM. Elevated Prevalence of 35–44 FMR1 Trinucleotide Repeats in Women with Diminished Ovarian Reserve. Reprod Sci. 2012;19(11):1226–31.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Peprah E. Fragile X Syndrome: The FMR1 CGG Repeat Distribution Among World Populations. Ann Hum Genet. 2011. doi:10.1111/j.1469-1809.2011.00694.x.

    PubMed  PubMed Central  Google Scholar 

  21. Rohr J, Allen EG, Charen K, Giles J, He W, Dominguez C, et al. Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study. Hum Reprod. 2008;23(5):1220–5. doi:10.1093/humrep/den050.

    Article  PubMed  CAS  Google Scholar 

  22. Schuh-Huerta SM, Johnson NA, Rosen MP, Sternfeld B, Cedars MI, Reijo Pera RA. Genetic variants and environmental factors associated with hormonal markers of ovarian reserve in Caucasian and African American women. Hum Reprod. 2012;27(2):594–608. doi:10.1093/humrep/der391.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Scott Jr RT, Hofmann GE. Prognostic assessment of ovarian reserve. Fertil Steril. 1995;63(1):1–11.

    PubMed  Google Scholar 

  24. Scriver J, Baker V, Young S, Behr B, Pastore L. Inter-laboratory validation of the measurement of follicle stimulating hormone (FSH) after various lengths of frozen storage. Reprod Biology Endocrin. 2010;8(1):145.

    Article  CAS  Google Scholar 

  25. Sharara FI, Scott JRT, Seifer DB. The detection of diminished ovarian reserve in infertile women. Am J Obstet Gynecol. 1998;179(3):804–12.

    Article  PubMed  CAS  Google Scholar 

  26. Sherman SL. Premature ovarian failure in the fragile X syndrome. Am J Med Genet. 2000;97:189–94.

    Article  PubMed  CAS  Google Scholar 

  27. Sowers M, McConnell D, Gast K, Zheng H, Nan B, McCarthy JD. Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril. 2010;94(4):1482–6. doi:10.1016/j.fertnstert.2009.07.1674.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  28. Spath MA, Feuth TB, Allen EG, Smits AP, Yntema HG, van Kessel AG, et al. Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers. Hum Reprod. 2011;26(8):2185–91. doi:10.1093/humrep/der146.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  29. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimullerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril.90(2):395–400

  30. Streuli I, Fraisse T, Ibecheole V, Moix I, Morris MA, de Ziegler D. Intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency. Fertil Steril. 2009;92(2):464–70.

    Article  PubMed  CAS  Google Scholar 

  31. Taieb J, Olivennes F, Birr AS, Benattar C, Righini C, Frydman R, et al. Comparison of day 3 FSH serum values as determined by six different immunoassays. Hum Reprod. 2002;17(4):926–8.

    Article  PubMed  CAS  Google Scholar 

  32. Therneau T. Survival: A Package for Survival Analysis in S. R package 2.37-2 edition ed2012.

  33. Visser JA, Themmen AP. Anti-Mullerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234(1–2):81–6. doi:10.1016/j.mce.2004.09.008.

    Article  PubMed  CAS  Google Scholar 

  34. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10(2):77–83.

    Article  PubMed  CAS  Google Scholar 

Download references


We thank the participants in this study, the study co-investigators who are not also co-authors (Dr. Lawrence Silverman, University of Virginia; Dr. Joel Finkelstein, Massachusetts General Hospital). All AMH testing was conducted at the Radioimmunoassay Core of the Reproductive Endocrine Sciences Center, Massachusetts General Hospital under the direction of Dr. Patrick Sluss. We are grateful to Carolina Conceptions for allowing recruitment through their clinic in North Carolina. We also thank the clinical research coordinators at all participating clinics: Parchayi Dalal, Hannah Spencer, Amy Brown, Amanda DeSmit, Angie Morey, Rebecca Briggs, and Janetta Phillips. This work was supported by the Eunice K. Shriver National Center for Child Health and Human Development at the National Institutes of Health (grants HD057485, HD052768 and HD068440 to Lisa Pastore). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Lisa M. Pastore.

Additional information

Capsule Among 79 women with Diminished Ovarian Reserve, the association between AMH and age was significantly different for women with ≥ 35 FMR1 CGG repeats than for women with < 35 repeats.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pastore, L.M., McMurry, T.L., Williams, C.D. et al. AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level. J Assist Reprod Genet 31, 1295–1301 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: